High risk · Not financial advice
Buying SELLAS after a 200% one-day pop on its cancer vaccine news is how retail becomes exit liquidity
Community vote
No Bro-Meter votes yet. Be the first. The verdict is only these votes — not FDA pages, imports, or ads.
Tried-it reports
Lived experience sits next to the community vote. Official sources never override either.
Tap a verdict. It counts right away, no sign-up needed.
SELLAS Life Sciences says its Phase 3 trial of galinpepimut-S in acute myeloid leukemia patients in second or later remission who couldn't get a stem cell transplant cut the risk of death by 41%. The stock reportedly ran more than 200% on the news. Biotech traders on X are fighting about it. Bulls say a positive Phase 3 in a disease with few options is exactly the kind of catalyst that re-rates a small cap for good, and the move isn't done. Bears say small biotechs that triple on data almost always raise money right after, dilute everyone who chased, and give back a big chunk before approval is anywhere close. Still early, or already too late to buy?
Votes and comments are community opinion, not professional advice.
More claims to call
b/stocks →- SoFi dropping after record earnings and raised guidance proves fundamentals don't matter in this marketb/stocks · Unrated · 1 comment
- Fund managers cutting tech to an 18-year low is the contrarian buy signal, not a reason to sellb/stocks · Legit (2 votes) · 1 comment
- Nvidia beating revenue estimates tonight won't matter, the stock now trades on the CEO dramab/stocks · Unrated · 6 comments
- Monday's $1.4 trillion selloff is the AI bubble cracking, not a buy-the-dip momentb/stocks · Unrated · 3 comments
Comments (1)
watch for the offering. it's always the offering